Hengrui Pharmaceutical Co., Ltd. 4 directors, supervisors and senior executives reduce shares through centralized bidding

Pharmaceutical intelligence news learned that on December 6, Hengrui pharmaceutical released a notice on the plan of reducing shares held by directors, supervisors and senior executives through centralized bidding The announcement shows that as of the date of disclosure of this announcement, sun Hui, Liu Jiang, sun Xugen and Tao Weikang, senior executives of Jiangsu Hengrui Pharmaceutical Co., Ltd (hereinafter referred to as "the company"), hold 3998080 shares of the company, accounting for 0.0904% of the total shares of the company Due to the demand of personal funds, sun Hui, Liu Jiang, sun Xugen and Tao Weikang, senior managers, reduced the total shares of the company by means of centralized competitive trading from December 30, 2019 to June 26, 2020 by no more than 626000 shares (accounting for 0.0142% of the total shares of the company) During the implementation of the reduction plan, in case of dividend distribution, bonus share distribution, share capital increase, new share issuance or share allotment and other equity ex rights and ex dividend issues, the number of reduction will be adjusted accordingly The reduction price will be determined according to the market price at the time of implementation of the reduction 37